Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Manidipine 20 mg tablets versus Madiplot 20 mg under fed conditions in healthy Thai adults
TCTR20261006001Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of manidipine in hypertension (HTN) (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Maximum plasma concentration at 48.00 hour, Area under the plasma concentration-time curve to last observed concentration at 48.00 hour and 1 more. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
manidipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on TCTR20261006001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261006001.